The EU Commission opens antitrust investigation into competitors suspected illegal disparagement of Pharmacosmos’ main intravenous iron product


Holbaek, Denmark: The EU Commission has opened a formal antitrust investigation to assess whether Vifor Pharma has restricted competition against its blockbuster high-dose intravenous iron treatment medicine by illegally disparaging its closest – and potentially only – competitor in Europe on the market for intravenous iron treatment, Pharmacosmos.

The EU Commission’s decision to initiate an investigation is based on indications that Vifor Pharma may have been disparaging Monofer, Pharmacosmos’ high dose intravenous iron product, by spreading misleading information regarding its safety and thereby may have unduly hindered Monofer's uptake in the European Economic Area (‘EEA') where approximately 1.8 million patients annually are being treated with high-dose intravenous iron products.

This alleged abuse would ultimately harm patients by stifling competition from an innovative medicine.

Pharmacosmos, as the complainant, welcomes the EU Commission’s decision to open an in-depth and prioritized investigation into the alleged anticompetitive disparagement. Pharmacosmos believes this is a first important step to secure that competition in the market of iv iron happens based on the merits of the products.

Link to EU Antitrust Press Release:


Contact information

Tobias S. Christensen, COO
+45 5948 5959

Claes C. Strom, CCO
+45 5948 5959,


Tietoja julkaisijasta



Pharmacosmos Group, headquartered in Holbaek, Denmark, and founded in 1965, is a highly specialised company focused on carbohydrate chemistry and a global leader in the development of innovative treatments for patients suffering from iron deficiency and iron deficiency anaemia. With companies in the UK, Nordics, Germany, the USA, and China, as well as through partners, Pharmacosmos markets its products around the world. With a strong and ongoing commitment to R&D, Pharmacosmos is able to leverage a unique carbohydrate production platform along with deep expertise in the synthesis of iron-carbohydrate complexes. The Pharmacosmos Group has approximately 500 employees.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat tiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.